ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$68.05 USD
+2.17 (3.29%)
Updated May 10, 2024 04:00 PM ET
After-Market: $67.97 -0.08 (-0.12%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.05 USD
+2.17 (3.29%)
Updated May 10, 2024 04:00 PM ET
After-Market: $67.97 -0.08 (-0.12%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
by Zacks Equity Research
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
by Zacks Equity Research
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Will Petrobras (PBR) Report Q1 Earnings Beat on Output Gains?
by Zacks Equity Research
Petrobras (PBR) beat the Zacks Consensus Estimate in two of the last four quarters and missed in the other two, which resulted in an earnings surprise of 2.8%, on average.
Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP)
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
What Will Sitio Royalties' (STR) Q1 Earnings Unveil?
by Zacks Equity Research
Sitio Royalties (STR) beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, resulting in an earnings surprise of 155.6%, on average.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.